Chordate Medical Holding AB (CMH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chordate Medical Holding AB (CMH) has a cash flow conversion efficiency ratio of -0.514x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.14 Million ≈ $-768.45K USD) by net assets (Skr13.90 Million ≈ $1.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chordate Medical Holding AB - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Chordate Medical Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Chordate Medical Holding AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Chordate Medical Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chordate Medical Holding AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Electricity Generating Public Company Limited
F:ECGF
|
0.000x |
|
Ukrproduct Group
LSE:UKR
|
0.310x |
|
XLMedia PLC
LSE:XLM
|
-0.008x |
|
WISHBONE GOLD PLC LS-001
F:7N6
|
N/A |
|
Anemoi International Ltd
LSE:AMOI
|
-0.089x |
|
Unicorn Mineral Resources PLC
LSE:UMR
|
N/A |
|
Premier African Minerals Ltd
LSE:PREM
|
-0.001x |
|
Sonder Holdings Inc
NASDAQ:SOND
|
0.040x |
Annual Cash Flow Conversion Efficiency for Chordate Medical Holding AB (2015–2024)
The table below shows the annual cash flow conversion efficiency of Chordate Medical Holding AB from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see CMH stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr9.20 Million ≈ $989.55K |
Skr-24.41 Million ≈ $-2.63 Million |
-2.654x | -46.89% |
| 2023-12-31 | Skr15.09 Million ≈ $1.62 Million |
Skr-27.26 Million ≈ $-2.93 Million |
-1.807x | +19.89% |
| 2022-12-31 | Skr11.07 Million ≈ $1.19 Million |
Skr-24.98 Million ≈ $-2.69 Million |
-2.256x | -332.08% |
| 2021-12-31 | Skr38.95 Million ≈ $4.19 Million |
Skr-20.34 Million ≈ $-2.19 Million |
-0.522x | +23.19% |
| 2020-12-31 | Skr25.64 Million ≈ $2.76 Million |
Skr-17.43 Million ≈ $-1.88 Million |
-0.680x | +55.95% |
| 2019-12-31 | Skr10.98 Million ≈ $1.18 Million |
Skr-16.95 Million ≈ $-1.82 Million |
-1.543x | +8.48% |
| 2018-12-31 | Skr11.26 Million ≈ $1.21 Million |
Skr-18.99 Million ≈ $-2.04 Million |
-1.686x | -61.95% |
| 2017-12-31 | Skr18.24 Million ≈ $1.96 Million |
Skr-18.99 Million ≈ $-2.04 Million |
-1.041x | -219.15% |
| 2016-12-31 | Skr29.55 Million ≈ $3.18 Million |
Skr-9.64 Million ≈ $-1.04 Million |
-0.326x | +6.19% |
| 2015-12-31 | Skr35.72 Million ≈ $3.84 Million |
Skr-12.42 Million ≈ $-1.34 Million |
-0.348x | -- |
About Chordate Medical Holding AB
Chordate Medical Holding AB (publ), a medical technology company, engages in the development of products and solutions for neurostimulation treatment in Sweden. It offers Ozilia, a neuromodulation and medication-free treatment technology for chronic migraine and chronic rhinitis. The company was founded in 2005 and is based in Kista, Sweden.